CxBladder™ (Detect, Triage, Triage Enhanced, Monitor) Bladder Cancer Test
Bladder cancer often presents with micro or macrohematuria and requires further clinical evaluation for urothelial carcinoma. Confirmatory diagnostic procedures typically include cystoscopy and urine cytology. However, the incidence of urothelial cancer in patients presenting with hematuria varies, with only 0.5-5% of microhematuria cases and 10-15% of gross hematuria cases leading to a cancer diagnosis. The American Urological Association (AUA) recommends risk stratification for hematuria patients to optimize evaluation costs and limit invasive procedures like cystoscopy to high-risk individuals.
Cxbladder™ is a non-invasive, high-performance mRNA based biomarker test designed to stratify patients with hematuria into low and high risk categories for urothelial carcinoma. The high-risk group is further subdivided into low-impact tumors (e.g., low-grade non-invasive papillary tumor, papillary urothelial neoplasm of low malignant potential) and high-impact tumors (aggressive or high-grade urothelial carcinoma). Based on test results, cystoscopy is recommended for intermediate or high-risk patients.
The Cxbladder™ test functions as a rule-out test to help exclude the need for invasive procedures in patients with a low probability of bladder cancer. The test measures mRNA expression of five key genes associated with bladder cancer (MDK, CDK1, IGFBP5, HOXA13, and CXCR), alongside patient demographics such as age, sex, and smoking history, utilizing next-generation RNA sequencing technology. Studies indicate that Cxbladder™ has a 4.8-fold higher diagnostic yield compared to conventional urinary biomarkers for bladder cancer.
Provider: Cxbladder™ is provided by Pacific Edge Diagnostics USA, Ltd. More information is available at https://www.cxbladder.com/us/.
- Facilitates early and accurate detection of bladder cancer
- Aids in risk stratification of patients presenting with hematuria
- Helps determine the necessity of cystoscopy and urine cytology
- Enhance clinical decision-making by providing actionable results
Triage Results:
- The risk score is rated from 0.0 to 10.0.
- Patients with scores below 4.0 are classified as low risk.
Bladder Detect Results:
The Cxbladder™ detection score ranges from 0.00 to 10.00, categorized as follows:
- Normal Gene Expression Score (<0.12):
- 97% Negative Predictive Value (NPV), indicates high probability of no urothelial carcinoma (UC).
Elevated Gene Expression Score (0.12 – 0.23):
- 94% NPV, indicates low probability of UC; however, altered biomarker gene expression warrants further clinical evaluation.
High Gene Expression Score (≥ 0.23):
- 68% Positive Predictive Value (PPV), indicates high probability of UC.
Normal gene expression score: <0.12.
Urine collected in a sterile container.
Stability
- Ambient: 3 days
- Refrigerated: 1 week
- Frozen: 1 month
- J Urol. 2021 Dec;206(6):1380-1389. [PMID: 34348469]
- Urol Oncol. 2023 Jul;41(7):326.e1-326.e8. [PMID: 36868882]
- Eur Urol. 2019 Aug;76(2):238-243. [PMID: 31103391]
- Front Surg. 2021 May 13;8:659292. [PMID: 34055868]
- Adv Ther. 2017 May;34(5):1087-1096. [PMID: 28341930]